VALN - Valneva's single-shot chikungunya vaccine VLA1553 gets FDA priority review

• The U.S. Food and Drug Administration (FDA) granted priority review to Valneva ( NASDAQ: VALN ) application seeking approval of single-shot chikungunya vaccine candidate VLA1553.
• The FDA accepted the company's biologics license application (BLA) and is expected to make a decision by end of August.
• Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review.
• Earlier in February, the French drugmaker had said that it completed enrollment and vaccination in a phase 3 trial, dubbed VLA1553-321, of the chikungunya vaccine in adolescents and the results are expected in mid-2023.
• Chikungunya virus is spread to people via the bite of an infected mosquito.

For further details see: